Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Radboud University Medical Center
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Stanford University
Erasca, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Jonsson Comprehensive Cancer Center
Solve Therapeutics
Degron Therapeutics Co.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Taiwan University Hospital
Ikena Oncology
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Columbia University
Thomas Jefferson University